发明名称 Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto
摘要 A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
申请公布号 US9546135(B2) 申请公布日期 2017.01.17
申请号 US201514866212 申请日期 2015.09.25
申请人 Millendo Therapeutics, Inc. 发明人 Hunt, III Stephen Warren;Phillips Martin Douglas;Matunas Robert;Chen Herman;Betancourt Aimesther;Uzarama Charles;Thibert Roch
分类号 A61K9/50;C07C275/28;A61K9/20;C07C273/18;A61K31/17 主分类号 A61K9/50
代理机构 Seed IP Law Group LLP 代理人 Seed IP Law Group LLP
主权项 1. A solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride having a particle size distribution as follows: d(0.1) of about 2 μm, d(0.5) of about 12 μm, and a d(0.9) of about 49 μm.
地址 Ann Arbor MI US